Evidence map›Paper›PMID 30617860›Full record

ArticleJournal of the American Society for Mass Spectrometry2019

TiO

Fred A M G van Geenen, Maurice C R Franssen, Ville Miikkulainen, Mikko Ritala, Han Zuilhof, Risto Kostiainen, Michel W F Nielen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 4 countries.

Fred A M G van GeenenLaboratory of Organic Chemistry, Wageningen University, Stippeneng 4, 6708 WE, Wageningen, The Netherlands.
Maurice C R FranssenLaboratory of Organic Chemistry, Wageningen University, Stippeneng 4, 6708 WE, Wageningen, The Netherlands.
Ville MiikkulainenDepartment of Chemistry, University of Helsinki, P.O. Box 55, 00014, Helsinki, Finland.
Mikko RitalaDepartment of Chemistry, University of Helsinki, P.O. Box 55, 00014, Helsinki, Finland.
Han ZuilhofLaboratory of Organic Chemistry, Wageningen University, Stippeneng 4, 6708 WE, Wageningen, The Netherlands.
Risto KostiainenDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland.
Michel W F NielenLaboratory of Organic Chemistry, Wageningen University, Stippeneng 4, 6708 WE, Wageningen, The Netherlands. Michel.nielen@wur.nl.ORCID http://orcid.org/0000-0003-4634-0249
University of Helsinki · FIWageningen University & Research · NLTianjin University · CN

Funding

Nederlandse Organisatie voor Wetenschappelijk Onderzoek 053.21.111
6 · The paper itself

Abstract

In drug discovery, it is important to identify phase I metabolic modifications as early as possible to screen for inactivation of drugs and/or activation of prodrugs. As the major class of reactions in phase I metabolism is oxidation reactions, oxidation of drugs with TiO

Indexed as

AcetamidesAminophenolsAndrogen AntagonistsAndrogensAnilidesAnti-Anxiety AgentsAnti-Arrhythmia AgentsBuspironeCatalysisEquipment DesignHumansLasersLaser TherapyLightOxidation-ReductionPharmaceutical PreparationsAcetamidesAminophenolsandarineAndrogen AntagonistsAndrogensAnilidesAnti-Anxiety AgentsAnti-Arrhythmia AgentsBuspironeostarinePharmaceutical PreparationsTitaniumtitanium dioxideVerapamilAmbient ionizationLaser ablationMass spectrometryOxidationPhotocatalysisSelective androgen receptor modulatorTitanium dioxide

Identifiers

PMID30617860
PMCPMC6445813
OpenAlexW2909820328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.